MA55895A - Compositions d'oxymétazoline et procédés de traitement de troubles oculaires - Google Patents

Compositions d'oxymétazoline et procédés de traitement de troubles oculaires

Info

Publication number: MA55895A
Authority: MA; Morocco
Prior art keywords: oxymetazoline; compositions; methods; eye disorders; treating eye
Prior art date: 2019-05-06

Application number

MA055895A

Other languages

English (en)

Inventor

Tina Devries

David Jacobs

Original Assignee

Rvl Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-05-06

Filing date

2020-05-05

Publication date

2022-03-16

2020-05-05 Application filed by Rvl Pharmaceuticals Inc filed Critical Rvl Pharmaceuticals Inc

2022-03-16 Publication of MA55895A publication Critical patent/MA55895A/fr

Links

WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 title 2
208000030533 eye disease Diseases 0.000 title 1
239000000203 mixture Substances 0.000 title 1
229960001528 oxymetazoline Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Ophthalmology & Optometry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

MA055895A 2019-05-06 2020-05-05 Compositions d'oxymétazoline et procédés de traitement de troubles oculaires MA55895A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201962843819P	2019-05-06	2019-05-06
US201962844069P	2019-05-06	2019-05-06
US16/716,014 US10799481B1 (en)	2019-05-06	2019-12-16	Compositions and methods for treating ocular disorders
US16/715,998 US10814001B1 (en)	2019-05-06	2019-12-16	Oxymetazoline compositions

Publications (1)

Publication Number	Publication Date
MA55895A true MA55895A (fr)	2022-03-16

Family

ID=72750169

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA055895A MA55895A (fr)	2019-05-06	2020-05-05	Compositions d'oxymétazoline et procédés de traitement de troubles oculaires

Country Status (17)

Country	Link
US (11)	US10814001B1 (fr)
EP (1)	EP3965737A1 (fr)
JP (3)	JP7141420B2 (fr)
KR (3)	KR102410503B1 (fr)
CN (2)	CN117045596A (fr)
AU (1)	AU2020268329B2 (fr)
BR (1)	BR112021022404A2 (fr)
CA (1)	CA3139443A1 (fr)
CL (1)	CL2021002918A1 (fr)
CO (1)	CO2021015265A2 (fr)
IL (1)	IL287831A (fr)
MA (1)	MA55895A (fr)
MX (1)	MX2021013516A (fr)
PE (1)	PE20220384A1 (fr)
SG (1)	SG11202112272TA (fr)
WO (1)	WO2020227260A1 (fr)
ZA (2)	ZA202108950B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120225918A1 (en) *	2011-03-03	2012-09-06	Voom, Llc	Compositions and Methods for Non-Surgical Treatment of Ptosis
US10814001B1 (en) *	2019-05-06	2020-10-27	Rvl Pharmaceuticals, Inc.	Oxymetazoline compositions
WO2022187306A1 (fr)	2021-03-03	2022-09-09	Voom, Llc	Compositions et procédés de traitement de la blépharite
WO2023079427A1 (fr) *	2021-11-03	2023-05-11	Avaca Pharma Private Limited	Compositions ophtalmiques et procédés associés

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE51421B1 (en)	1980-08-01	1986-12-24	Smith & Nephew Ass	Ophthalmic compositions containing triamterene
US5459133A (en)	1992-06-05	1995-10-17	Telor Ophthalmic Pharmaceuticals, Inc.	Methods and products for treating presbyopia
US5888493A (en)	1996-12-05	1999-03-30	Sawaya; Assad S.	Ophthalmic aqueous gel formulation and related methods
DE10337186A1 (de) *	2003-08-13	2005-03-17	Merck Patent Gmbh	Wässrige Wirkstoff-Lösung
US7812049B2 (en)	2004-01-22	2010-10-12	Vicept Therapeutics, Inc.	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP2006131628A (ja) *	2004-10-08	2006-05-25	Rohto Pharmaceut Co Ltd	オキシメタゾリン含有水性組成物
US8758816B2 (en)	2004-11-24	2014-06-24	Meda Pharmaceuticals Inc.	Compositions comprising azelastine and methods of use thereof
US8466174B2 (en)	2006-03-17	2013-06-18	Johnson & Johnson Vision Care, Inc.	Methods for stabilizing oxidatively unstable compositions
WO2007127333A2 (fr)	2006-04-26	2007-11-08	Aciex, Inc.	Compositions pour le traitement et la prévention du gonflement des paupières
WO2008070185A2 (fr) *	2006-12-06	2008-06-12	The Trustees Of Columbia University In The City Of New York	Procédé de stabilisation de tissu oculaire humain par réaction avec du nitrite et des agents associés tels que des composés nitro
CN101951886A (zh) *	2007-12-21	2011-01-19	先灵-普劳健康护理产品公司	增强羟甲唑啉的光稳定性
SI2262506T1 (sl) *	2008-03-11	2014-07-31	Alcon Research, Ltd.	Močno flokulirane suspenzije triamcinolon acetonida z nizko viskoznostjo za intravitrealno injekcijo
JP2012528888A (ja) *	2009-06-05	2012-11-15	アーシエックスセラピューティックス，インコーポレイテッド	眼科用配合剤、その製造方法およびその使用方法
US20120082625A1 (en)	2010-09-28	2012-04-05	Michael Graeber	Combination treatment for rosacea
EP2637684A4 (fr) *	2010-11-08	2014-05-07	Healor Ltd	Compositions ophtalmiques tamponnées et leurs procédés d'utilisation
WO2012075319A2 (fr)	2010-12-03	2012-06-07	Allergan, Inc.	Compositions de crème pharmaceutique et leurs procédés d'utilisation
US20120225918A1 (en) *	2011-03-03	2012-09-06	Voom, Llc	Compositions and Methods for Non-Surgical Treatment of Ptosis
CA2870158C (fr)	2012-05-25	2017-10-24	Xlear, Inc.	Compositions anti-muqueuses a base de xylitol, procedes afferents et compositions afferentes
UA119324C2 (uk)	2013-04-02	2019-06-10	Теміс Медікер Лімітед	Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
US10039220B2 (en)	2013-09-18	2018-07-31	Mycronic AB	Method, system and device for improved storage and handling of components
CA2951725C (fr)	2014-06-11	2022-06-07	Allergan, Inc.	Formulations d'oxymetazoline stabilisees et leurs utilisations
EP3302426A4 (fr)	2015-05-29	2018-12-05	Sydnexis, Inc.	Formulations pharmaceutiques stabilisées de d2o
US20170312335A1 (en) *	2015-12-30	2017-11-02	Lubris Llc	Topical use of prg4 for treatment of allergy and symptoms of inflammation
CN108883308A (zh)	2016-01-26	2018-11-23	利维申制药有限公司	α-肾上腺素能药剂的组合物和用途
CN105997856A (zh) *	2016-06-24	2016-10-12	魏威	盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en)	2016-06-30	2022-02-15	The Procter And Gamble Company	Shampoo compositions comprising a chelant
US10814001B1 (en) *	2019-05-06	2020-10-27	Rvl Pharmaceuticals, Inc.	Oxymetazoline compositions

2019
- 2019-12-16 US US16/715,998 patent/US10814001B1/en active Active
- 2019-12-16 US US16/716,014 patent/US10799481B1/en active Active
2020
- 2020-03-16 JP JP2020045468A patent/JP7141420B2/ja active Active
- 2020-04-01 CN CN202310901249.9A patent/CN117045596A/zh active Pending
- 2020-04-01 CN CN202010249167.7A patent/CN111888326B/zh active Active
- 2020-04-27 KR KR1020200050837A patent/KR102410503B1/ko active Active
- 2020-05-05 AU AU2020268329A patent/AU2020268329B2/en active Active
- 2020-05-05 PE PE2021001852A patent/PE20220384A1/es unknown
- 2020-05-05 EP EP20729894.4A patent/EP3965737A1/fr active Pending
- 2020-05-05 CA CA3139443A patent/CA3139443A1/fr active Pending
- 2020-05-05 MA MA055895A patent/MA55895A/fr unknown
- 2020-05-05 BR BR112021022404A patent/BR112021022404A2/pt unknown
- 2020-05-05 MX MX2021013516A patent/MX2021013516A/es unknown
- 2020-05-05 WO PCT/US2020/031425 patent/WO2020227260A1/fr not_active Ceased
- 2020-05-05 SG SG11202112272TA patent/SG11202112272TA/en unknown
- 2020-10-05 US US17/063,416 patent/US10940138B2/en active Active
- 2020-10-07 US US17/064,915 patent/US10898573B1/en active Active
2021
- 2021-01-21 US US17/154,676 patent/US11103482B2/en active Active
- 2021-03-08 US US17/194,559 patent/US11324722B2/en active Active
- 2021-08-30 US US17/461,052 patent/US11311515B2/en active Active
- 2021-09-24 JP JP2021155526A patent/JP7705326B2/ja active Active
- 2021-11-04 IL IL287831A patent/IL287831A/en unknown
- 2021-11-05 CL CL2021002918A patent/CL2021002918A1/es unknown
- 2021-11-11 CO CONC2021/0015265A patent/CO2021015265A2/es unknown
- 2021-11-11 ZA ZA2021/08950A patent/ZA202108950B/en unknown
2022
- 2022-04-25 US US17/728,860 patent/US11541036B2/en active Active
- 2022-05-09 US US17/662,494 patent/US11701343B2/en active Active
- 2022-06-14 KR KR1020220072209A patent/KR102663319B1/ko active Active
- 2022-11-11 ZA ZA2022/12328A patent/ZA202212328B/en unknown
- 2022-12-23 US US18/146,127 patent/US20230355587A1/en active Pending
2023
- 2023-06-08 US US18/331,688 patent/US20240033250A1/en active Pending
2024
- 2024-04-29 KR KR1020240057166A patent/KR102859351B1/ko active Active
2025
- 2025-01-31 JP JP2025014721A patent/JP2025065198A/ja active Pending

Also Published As

Publication number	Publication date
AU2020268329A1 (en)	2022-01-06
JP2021191802A (ja)	2021-12-16
KR102410503B1 (ko)	2022-06-17
SG11202112272TA (en)	2021-12-30
CA3139443A1 (fr)	2020-11-12
US10799481B1 (en)	2020-10-13
US20210137889A1 (en)	2021-05-13
US20240033250A1 (en)	2024-02-01
US20220273621A1 (en)	2022-09-01
AU2020268329B2 (en)	2026-01-15
KR20200128629A (ko)	2020-11-16
BR112021022404A2 (pt)	2022-01-18
EP3965737A1 (fr)	2022-03-16
US10940138B2 (en)	2021-03-09
MX2021013516A (es)	2022-01-24
US11701343B2 (en)	2023-07-18
US20230355587A1 (en)	2023-11-09
US20210015795A1 (en)	2021-01-21
KR102663319B1 (ko)	2024-05-03
CN111888326A (zh)	2020-11-06
US11103482B2 (en)	2021-08-31
PE20220384A1 (es)	2022-03-18
US11324722B2 (en)	2022-05-10
US20220257566A1 (en)	2022-08-18
CL2021002918A1 (es)	2022-08-19
US20210212992A1 (en)	2021-07-15
KR20220084264A (ko)	2022-06-21
KR20240060580A (ko)	2024-05-08
US11541036B2 (en)	2023-01-03
JP7141420B2 (ja)	2022-09-22
US20210386711A1 (en)	2021-12-16
IL287831A (en)	2022-01-01
US10814001B1 (en)	2020-10-27
JP7705326B2 (ja)	2025-07-09
US10898573B1 (en)	2021-01-26
ZA202108950B (en)	2023-10-25
ZA202212328B (en)	2025-03-26
US20200353083A1 (en)	2020-11-12
JP2020183373A (ja)	2020-11-12
CO2021015265A2 (es)	2022-02-28
JP2025065198A (ja)	2025-04-17
NZ782902A (en)	2024-09-27
US11311515B2 (en)	2022-04-26
US20210023222A1 (en)	2021-01-28
CN111888326B (zh)	2023-07-21
WO2020227260A1 (fr)	2020-11-12
KR102859351B1 (ko)	2025-09-12
CN117045596A (zh)	2023-11-14

Publication	Publication Date	Title
EP3924481A4 (fr)	2023-01-25	Compositions et méthodes de traitement d'hémoglobinopathies
MA55895A (fr)	2022-03-16	Compositions d'oxymétazoline et procédés de traitement de troubles oculaires
EP3781214A4 (fr)	2022-04-13	Compositions et procédés de traitement de l'amyotrophie spinale
MA54874A (fr)	2021-12-08	Compositions et procédés de traitement des troubles neurocognitifs
MA54880A (fr)	2021-12-08	Compositions et procédés de traitement de troubles neurocognitifs
MA45798A (fr)	2019-06-05	Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA53873A (fr)	2022-01-19	Compositions et procédés pour le traitement de la presbytie
EP3423100A4 (fr)	2019-10-16	Compositions destinées à traiter l'inflammation et méthodes de traitement associées
EP4247367A4 (fr)	2024-10-16	Formulations et procédés de traitement d'affections de l'?il
EP3955937A4 (fr)	2023-01-18	Composés et procédés pour le traitement de troubles oculaires
EP3866790A4 (fr)	2022-08-03	Méthodes et compositions permettant le traitement du glaucome et d'affections apparentées
EP4297871A4 (fr)	2025-01-01	Procédés et compositions pour le traitement de l'agitation
MA52631A (fr)	2021-03-24	Compositions et méthodes pour le traitement de la maladie de parkinson
MA54792A (fr)	2021-12-01	Compositions et méthodes pour le traitement de la maladie de parkinson
EP4041312A4 (fr)	2023-12-20	Procédés de traitement d'un trouble oculaire
EP3873525A4 (fr)	2022-07-13	Compositions et procédés de traitement d'une lésion cérébrale
EP3644983A4 (fr)	2021-04-07	Compositions et méthodes de traitement ou de prévention d'affections pulmonaires fibreuses
EP3979996A4 (fr)	2023-06-14	Méthodes et compositions de traitement de troubles de la vue
CA3236794A1 (fr)	2025-06-17	Compositions et methodes pour le traitement de l'epilepsie
EP3955926A4 (fr)	2022-11-30	Composés et procédés pour le traitement de troubles oculaires
EP4045046A4 (fr)	2024-01-10	Procédés et compositions pour le traitement de troubles liés au fer
EP3962545A4 (fr)	2023-01-25	Compositions et procédés pour le traitement de la dégénérescence rétinienne
EP4099997A4 (fr)	2024-05-15	Méthodes et compositions pour le traitement de maladies
EP3813794A4 (fr)	2022-07-13	Compositions ophtalmiques et méthodes de traitement de troubles oculaires
MA54873A (fr)	2021-12-08	Compositions et méthodes pour le traitement de troubles neurocognitifs